These conflicting reports, in addition to a lack of studies observing the role of other anti-apoptotic factors in ERα+ breast cancer resistance, led us to further explore the role of Bcl-2, as well as Bcl-xL and Mcl-1, in response of ERα+ breast cancers to endocrine inhibition. Here, BCL2L1 is linked to breast carcinoma.